An interventional study of Maximal incremental exercise test in Beta Thalassemia Transfusion Dependent, sponsored by Centre Hospitalier Metropole Savoie. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Centre Hospitalier Metropole Savoie · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in beta-Thalassemia with a site in France — 2 open to participants now, 5 under way, 3 of them phase 3. beta-Thalassemia · France.
Among the 11 studies in beta-Thalassemia with a site in France, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 2 with no phase, and was the 11th registered.
295 studies on the registry are indexed under beta-Thalassemia; 70 are open to participants now.
Browse beta-Thalassemia studies →2 of the 11 studies in beta-Thalassemia with a site in France are open now. Recruiting first, the newest first:
Celgene · Sites in France, United States, Australia and 19 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 6
First in 2010; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 36 is close to the median of 40 across 209 interventional studies indexed under beta-Thalassemia.
Median enrollment 41 across the 10 interventional studies, 66 across the 1 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 5 most frequent:
Centre Hospitalier Metropole Savoie is the lead sponsor of 22 studies on the registry; 8 are open to participants now.
Centre Hospitalier Metropole Savoie has 1 study filed under beta-Thalassemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in beta-Thalassemia with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare physical ability of patients with transfusion-dependent β-thalassemia to control subjects. The main question it aims to answer is:
is there a difference in power output at first lactate threshold between patients with transfusion-dependent β-thalassemia and control subjects during maximal incremental exercise test.
Participants will have to realise differents exams including measurement of body compposition, maximal incremental exercise test, vertical jump, vasoreactivity test, blood sampling, quality of life questionnaires and neuromuscular assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients aged 18 years or older
Control subjects must meet all of the following criteria to participate in the study:
Exclusion Criteria:
control participant without Beta thalassemia
Other: Maximal incremental exercise test
same intervention than control group
Other: Maximal incremental exercise test
Participants will perform a symptom-limited maximal incremental exercise test on a cycle ergometer.
Power at the first lactate threshold (PSL1) collected during the maximal incremental exercise test, compared between the two groups
Participants perform a maximal incremental exercise test on a cycle ergometer. The protocol includes one-minute intervals, with increments and initial power varying according to the subject's age and gender. The exercise continues until the subject is unable to maintain the power imposed by the current level. A drop of blood sample is taken from the earlobe and immediately analyzed to measure blood lactate concentration and determine first lactate threshold.
Time frame: 7 days after a transfusion for patient
Comparison of power values at lactate threshold 2 between βTTD patients and control subjects.
During the exercise test, a drop of blood is taken from the earlobe and immediately analyzed to measure blood lactate concentration and determine secondlactate threshold (LT2).
Time frame: 7 days after a transfusion for patients
Comparison between βTTD patients and control subjects of oxygen consumption efficiency slope values (OUES for Oxygen Uptake Efficiency Slope)
Cardio-pulmonary parameters are measured continuously throughout the maximum incremental exercise test and are used to calculate, among other things, the oxygen uptake efficiency slope (OUES), an indicator of the subject's ability to transport and use oxygen.
Time frame: 7 days after a transfusion for patients
Comparison between βTTD patients and control subjects of cardiac output values combining heart rate and systolic ejection volume values during maximal exercise.
Values will be recorder during maximal incremental exercise test. Heart rate and systolic ejection volume values is continuously recorded by bioimpedance measurement.
Time frame: 7 days after a transfusion for patients
Comparison of muscle mass values between βTTD patients and control subjects
A body composition measurement will be performed using bioimpedance analysis.
Time frame: 7 days after a transfusion for patients
Comparison between βTTD patients and control subjects of first-second expiratory flow values (FEV1, L)
A spirometry test will be performed. After taking a deep breath, the participant will be asked to exhale as quickly as possible into the spirometer.
Time frame: 7 days after a transfusion for patients
Comparison between βTTD patients and control subjects of maximum grip strength, jump height and reactive strength index values
Jump height will be evaluate using video analysis.
Time frame: 7 days after a transfusion for patients
Compare neuromuscular function between βTTD patients and control subjects
Nerve conduction will be assessed by electroneuromyography (ENMG). Muscle electrical activity will be measured by ENMG following low-intensity electrical stimulation to collect the F wave. This test will measure: nerve conduction velocity, latency between nerve stimulation and response, response amplitude, and response duration.
Time frame: 7 days after a transfusion for patients
Compare the level of physical activity between βTTD patients and control subjects
Level of activvity will be assessed with of International Physical Activity Questionnaire
Time frame: During inclusion visit, at day 1
Compare anxiety levels between βTTD patients and control subjects.
score to HADS questionnaire
Time frame: During second visit, occuring during a transfusion visit and no longer than 3 months after the inclusion.
Comparison between βTTD patients and control subjects of muscle reoxygenation slope values upon removal of arterial occlusion
A vasoreactivity test will then be performed at rest following venous occlusion, in order to measure the ability to reoxygenate the tissue.
Time frame: 7 days after a transfusion for patients
Correlation within the βTTD group between physical ability and cardiac iron load, hepatic iron load and EPO
Correlation within the βTTD group between power at lactate threshold 1 (see primary outcome) and cardiac T2\* , hepatic iron concentration and EPO level wich will be taken in patient medical file
Time frame: 7 days after a transfusion for patients
Correlation within the βTTD group between testosterone (men) or oestrogen (women) levels and muscle mass in kg
data collected in patient medical file
Time frame: 7 days after a transfusion for patients
Correlation within the βTTD group between quality of life and physical ability
SF36 questionnaire will be done and scoore will be correlated to power at first lactic threshold
Time frame: During second visit, occuring during a transfusion visit and no longer than 3 months after the inclusion.
Assessing the link between perceived fatigue and physical activity levels in βTTD patients
Correlation between the score at FACIT-F questionnaires compared to scores at IPAQ questionnaires
Time frame: During second visit, occuring during a transfusion visit and no longer than 3 months after the inclusion.
Assessing the link between physical fitness and fatigue/pain experienced by βTTD patients
Correlation within the βTTD group between power at lactate threshold 1 and FACIT-F and BPI scores (multivariate analysis).
Time frame: During second visit, occuring during a transfusion visit and no longer than 3 months after the inclusion.
Assessing the link between microvascular vasoreactivity, inflammation and haemolysis in βTTD patients
Correlation within the βTTD group between the reoxygenation slope and blood concentrations of CRP, LDH, and indirect bilirubin
Time frame: 7 days after transfusion for patients
Assessing motivation for physical activity in βTTD patients
Description of the EMAPS score
Time frame: During second visit, occuring during a transfusion visit and no longer than 3 months after the inclusion.
Comparison between βTTD patients and control subjects of vital capacity (VC, L)
A spirometry test will be performed. After taking a deep breath, the participant will be asked to exhale as quickly as possible into the spirometer.
Time frame: 7 days after a transfusion for patients
Comparison between βTTD patients and control subjects of maximum exercise ventilation (VE, L.min-1)
The ventilation rate will be continuously monitored during CPET. The ventilation rate value corresponding to the time of maximal exercise based on oxygen consumption will be used.
Time frame: 7 days after a transfusion for patients
Comparison between βTTD patients and control subjects of maximum grip strength (kg)
Maximum grip strength will be assessed with a hand dynamometer.
Time frame: 7 days after a transfusion for patients
Comparison between βTTD patients and control subjects of reactive strength index values
Reactive strength index values will be calculated based on jump height divided by the time to take-off
Time frame: 7 days after a transfusion for patients
Plan to share: No
Started Sep 2025 (actual). Primary completion is estimated for Oct 2028, 37 months after the start.
Of 29 interventional studies with no phase under beta-Thalassemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 69. This study's planned 37 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Metropole Savoie